- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04442815
EIT in Patient Ventilator Asynchrony
Analysis of Patient Ventilator Asynchrony Using Electrical Impedance Tomography (EIT) in Patients With Acute Respiratory Failure
Study Overview
Status
Conditions
Detailed Description
Patients and Methods:
Admitted ventilated patients who are greater than 18 years old and fulfilled the Berlin's diagnostic criteria of moderate to severe ARDS will be selected to enter our study. The exclusion criteria include (1) patients with metallic materials in the body (including wire, pin or implanted electrical devices etc.); (2) patients with cutaneous diseases which prohibited the application of electrode leads to attached the body; (3) severe chronic obstructive pulmonary diseases; (4) hemodynamically unstable; (5) proved barotrauma (including pneumothorax or pneumomediastinum etc.); (6) pregnancy; (7) diseases characterized with increased intracranial pressure; (8) patients or family who refused the informed consent. All patients who fulfilled the diagnosis of ARDS will receive standard care of low tidal volume ventilator therapy. The tidal volume 6 ml/Kg will be used. The investigators expect to enroll at least 20 analyzable cases. Sedation and paralysis are usually used in moderate to severe ARDS patients and daily interruption of sedation and paralysis is a standard practice. The investigators will perform recording during daily interruption of sedation and paralysis, up to 60 minutes period will be recorded during the interruption period. Recording will be done at least once for registered case and could be repeated in case of unsatisfactory signals.
Instrumentation In all patients, air flow will be measured using a pneumotachograph (Hamilton AG, or Hans Rudolf) connected to a differential pressure transducer (MP 45, Validyne Corp., Northridge, CA). The flow sensor will be placed between the endotracheal tube and the Y-piece of the ventilator. Tidal volume will be obtained by integrating the flow signal. Airway pressure and esophageal pressure will be measured using differential pressure transducers (P300D, Validyne Corp., Northridge, CA.). An appropriate esophageal pressure signal will be confirmed according to the standard guideline[27]. All signals are sampled and digitalized at 200 Hz and data are stored in a data acquisition system (MP150, Acqknowledgement, Biopac, Goleta, CA).
Measurements:
Electrical impedance tomography:
The investigators use a commercial EIT monitor (PulmoVista 500, Drager Medical GmbH, Lubeck, Germany). An electrode belt with 16 equally spaced electrodes will be placed around the patient's thorax at the 4th to 5th intercostal space. Impedance data will be acquired by applying adjacent alternate current injection (50 KHz) and measuring the voltage difference between the adjacent leads and a finite element method-based, linearized Newton-Raphson reconstruction algorithm is used to construct the impedance data. The PulmoVista 500 monitor displays functional EIT images, i.e. relative impedance changes including tidal ventilation and end-expiratory lung impedance (EELI) changes. During the study phases, EIT data will be registered at 20-40 Hz and low-pass filtered (35 per minute) and stored for offline analysis.
The individual impedance recording (10 minutes per segment) will be linked into a single file and impedance calculation will thus be done off-line. The investigators will subdivide the impedance recordings into ventral to dorsal parts. The investigators define the presence of pendelluft as the presence of opposite impedance change (△Z) between dependent and independent zones during a breathing effort. The breath could occur in inspiration phase, expiratory phase or in transition. Estimation of volume of pendelluft will be determined by the integrated volume and corresponding impedance change.
Respiratory mechanics:
The investigators will record the peak and plateau airway pressure, total PEEP, flow and the esophageal pressure. Transpulmonary pressure (PL) will be calculated as the difference between Paw and Pes calculate the transpulmonary pressure.
Study protocol The investigators target at moderate to severe ARDS patients who are already under deep sedation with neuromuscular blockade. As daily interruption of sedatives and muscle relaxant are routinely performed in our ICU, we will record the respiratory mechanics and EIT data for about one hour which should include both controlled and spontaneous breathing period.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Chang-Wen Chen, MD
- Phone Number: 2587 886-6-2353535
- Email: cwchen@mail.ncku.edu.tw
Study Contact Backup
- Name: Thy-Sheng Lin, MD
- Phone Number: 3635 886-6-2353535
- Email: em73635@mail.hosp.ncku.edu.tw
Study Locations
-
-
-
Tainan, Taiwan, 704
- Chang-Wen Chen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Clinical diagnosis of moderate to severe ARDS
Exclusion Criteria:
- Severe chronic obstructive pulmonary diseases
- Proved barotrauma (including pneumothorax or pneumomediastinum etc.);
- Pregnancy
- Diseases characterized with increased intracranial pressure
- Patients or family who refused the informed consent.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient ventilator asynchrony
Time Frame: up to 1 hour following interruption of muscle relaxant
|
Various types of patient ventilator asynchrony
|
up to 1 hour following interruption of muscle relaxant
|
Regional ventilation distribution by EIT
Time Frame: up to 1 hour following interruption of muscle relaxant
|
Regional ventilation distribution by EIT in various types of patient ventilator asynchrony
|
up to 1 hour following interruption of muscle relaxant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
hospitalization day and final outcome
Time Frame: up to 3 months
|
duration of hospitalization and hospital mortality
|
up to 3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chang-Wen Chen, MD, National Cheng-Kung University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EIT and ARF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ARDS, Human
-
Bicetre HospitalUnknown
-
Biozeus Biopharmaceutical S.A.InCor Heart InstituteTerminatedPulmonary Disease | ARDS | ARDS, HumanBrazil
-
Implicit BioscienceNo longer availableCOVID | SARS-CoV2 | ARDS, Human | ArdsItaly
-
National University Health System, SingaporeActive, not recruiting
-
King Abdul Aziz Specialist HospitalCompleted
-
Southeast University, ChinaCompleted
-
Magni FedericoUnknown
-
Wolfson Medical CenterUnknown